A3907

A3907 is a first-in-class, orally bioavailable, systemic small molecule inhibitor of the **apical sodium-dependent bile acid transporter** (ASBT). Unlike previous ASBT inhibitors, A3907 inhibits ASBT not only in the ileum but also in the kidney and cholangiocytes, promoting both fecal and urinary excretion of bile acids. By blocking bile acid reabsorption via the ASBT, A3907 aims to reduce toxic bile acid accumulation, offering potential therapeutic benefit in adult cholestatic liver diseases, such as **primary sclerosing cholangitis (PSC)** and **primary biliary cholangitis (PBC)**. Preclinical data show efficacy in reducing markers of liver injury, and Phase 1 clinical studies demonstrate favorable safety, tolerability, and pharmacokinetics.